NDLI: Implementable Strategies and Exploratory Considerations to Reduce Costs Associated with Anti-TNF Therapy in Inflammatory Bowel Disease

Content Provider	PubMed Central
Author	Park, Kt Crandall, Wallace V. Fridge, Jacqueline Leibowitz, Ian H. Tsou, Marc Dykes, Dana Hoffenberg, Edward J. Kappelman, Michael D. Colletti, Richard B.
Abstract	A health care system is needed where care is based on the best available evidence and is delivered reliably, efficiently, and less expensively (best care at lower cost). In gastroenterology, anti-tumor necrosis factor (anti-TNF) agents represent the most effective medical therapeutic option for patients with moderate-to-severe inflammatory bowel disease (IBD), but are very expensive and account for nearly a quarter of the cost of IBD care, representing a major area of present and future impact in direct health care costs. The ImproveCareNow Network, consisting of over 55 pediatric IBD centers, seeks ways to improve the value of care in IBD – curtailing unnecessary costs and promoting better health outcomes through systematic and incremental quality improvement initiatives. This report summarizes the key evidence to facilitate the cost-effective use of anti-TNF agents for patients with IBD. Our review outlines the scientific rationale for initiating cost-reducing measures in anti-TNF use and focuses on three implementable strategies and four exploratory considerations through practical clinical guidelines, as supported by existing evidence. Implementable strategies can be readily integrated into today’s daily practice, while exploratory considerations can guide research to support future implementation.
Related Links	http://dx.doi.org/10.1097/01.mib.0000441349.40193.aa
Ending Page	951
Page Count	6
Starting Page	946
File Format	PDF
ISSN	10780998
e-ISSN	15364844
Journal	Inflammatory bowel diseases
Issue Number	5
Volume Number	20
Language	English
Publisher Date	2014-05-01
Access Restriction	Open
Subject Keyword	Immunology and Allergy Gastroenterology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Gastroenterology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with Inflammatory Bowel Disease

Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease

AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease

The influence of anti-TNF agents on hemoglobin levels of patients with inflammatory bowel disease

Non-Drug Costs Associated with Outpatient Infliximab Administration in Pediatric Inflammatory Bowel Disease

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease

Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease

Immune Response to Influenza A/H1N1 Vaccine in Inflammatory Bowel Disease Patients Treated with Anti TNF-α Agents: Effects of Combined Therapy with Immunosuppressants

Implementable Strategies and Exploratory Considerations to Reduce Costs Associated with Anti-TNF Therapy in Inflammatory Bowel Disease

Similar Documents

Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with Inflammatory Bowel Disease

Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease

AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease

The influence of anti-TNF agents on hemoglobin levels of patients with inflammatory bowel disease

Non-Drug Costs Associated with Outpatient Infliximab Administration in Pediatric Inflammatory Bowel Disease

The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study

Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease

Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease

Immune Response to Influenza A/H1N1 Vaccine in Inflammatory Bowel Disease Patients Treated with Anti TNF-α Agents: Effects of Combined Therapy with Immunosuppressants

Implementable Strategies and Exploratory Considerations to Reduce Costs Associated with Anti-TNF Therapy in Inflammatory Bowel Disease